NCT05835466 - Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 24, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Myelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF)

Interventions

DRUG

reparixin

reparixin at 1200mg TID three times per day.

Trial Locations (9)

10029

RECRUITING

Ruttenberg Treatment Center, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

NewYork-Presbyterian/Weill Cornell Medical Center, New York

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

27157

RECRUITING

Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem

30322

NOT_YET_RECRUITING

Emory University, Atlanta

33612

RECRUITING

Moffitt Cancer Center, Tampa

43210

NOT_YET_RECRUITING

The Ohio State University, Columbus

44195

NOT_YET_RECRUITING

The Cleveland Clinic Foundation, Cleveland

All Listed Sponsors

collaborator

Dompé Farmaceutici S.p.A

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER